{"title": "A dendritic cell-based vaccine for treating HIV infection: background and preliminary results - IOZK", "author": "Root", "url": "https://www.iozk.de/2007/02/a-dendritic-cell-based-vaccine-for-treating-hiv-infection-background-and-preliminary-results/", "hostname": "iozk.de", "description": "PMID: 17241177 Journal: Journal of internal medicine (volume: 261, issue: 2, J. Intern. Med. 2007 Feb;261(2):123-31) Published: 2007-02-01 Authors: Andrieu JM, Lu W ABSTRACT Antibody response against human immunodeficiency virus-1 (HIV) is ineffective and cellular immune response is not strong enough to achieve the complete suppression or at least a strong control of viral replication [\u2026]", "sitename": "IOZK", "date": "2007-02-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "[A dendritic cell-based vaccine for treating HIV infection: background and preliminary results ](https://www.iozk.de/2007/02/a-dendritic-cell-based-vaccine-for-treating-hiv-infection-background-and-preliminary-results/)\nABSTRACT\nAntibody response against human immunodeficiency virus-1 (HIV) is ineffective and cellular immune response is not strong enough to achieve the complete suppression or at least a strong control of viral replication in HIV- infected patients. In 2001, we showed in vitro that dendritic cells (DCs) of HIV-infected patients loaded with autologous HIV chemically inactivated by aldrithiol-2 were capable of raising an HIV-specific cellular immune response powerful enough to allow the destruction of autologous HIV- infected CD4 T cells. In 2003, we showed that simian immunodeficiency virus (SIV)-infected macaques vaccinated with inactivated SIV-loaded autologous DCs raised a strong SIV-specific cellular response. Ten months after vaccination, plasma viral load of 7 out of the 10 vaccinated monkeys remained 1000-fold lower than initially. In December 2004, we published results observed in 18 untreated HIV-infected patients vaccinated with autologous monocyte-derived DCs loaded with autologous inactivated HIV. A year following vaccination, 8 patients had a plasma viral load decrease >90%; among them, 4 had viral load <1000 copies mL(-1). Moreover, by one year, the viral load decline of the 18 patients was significantly correlated with their percentage of HIV-1-gag-specific CD8(+) T cells expressing perforin and that of HIV-1-specific CD4(+) T(H)1 cells. This is the first demonstration of the capacity of a therapeutic vaccine to induce an effective HIV-specific T cell response associated with sustained viral suppression in untreated viremic patients. The manipulation of antigen presenting cells to elicit virus-specific cellular responses is a promising tool to control persistant viral infections.", "language": null, "image": null, "pagetype": "article", "links": ["https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.primomedico.com/fr/medecin/iozk-centre-immunologie-et-oncologie-de-cologne/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.primomedico.com/ar/tabib/iozk-mrkz-elm-almnaep-alsrtany-fy-koln/", "mailto:info@iozk.de", "https://www.iozk.de/2007/02/a-dendritic-cell-based-vaccine-for-treating-hiv-infection-background-and-preliminary-results/", "https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.iozk.de/", "/", "#", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "#", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "#", "https://www.iozk.de/iozk-publikationen/", "https://www.iozk.de/publikationen/", "https://www.iozk.de/fachwissen/", "https://www.iozk.de/aktuelles/", "https://www.iozk.de/kontakt/", "?s=", "#", "https://www.iozk.de/2007/02/a-dendritic-cell-based-vaccine-for-treating-hiv-infection-background-and-preliminary-results/", "https://www.iozk.de/category/publications/hiv-aids/", "https://www.iozk.de/category/publications/", "#", "https://www.ncbi.nlm.nih.gov/pubmed/17241177", "mailto:?subject=A%20dendritic%20cell-based%20vaccine%20for%20treating%20HIV%20infection%3A%20background%20and%20preliminary%20results&body=https://www.iozk.de/2007/02/a-dendritic-cell-based-vaccine-for-treating-hiv-infection-background-and-preliminary-results/", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/portfolio-item/evidenzbasierte-medizin-am-iozk/", "https://www.iozk.de/portfolio-item/laboratorien-am-iozk/", "https://www.iozk.de/portfolio-item/magazin-der-iozk-stiftung-consilium/", "https://www.iozk.de/portfolio-item/video-patient-berichtet-ueber-die-erfahrungen-mit-der-iozk-immuntherapie/", "https://www.iozk.de/portfolio-item/video-patientin-frau-ebel-ueber-ihre-erfahrungen-mit-der-iozk-immuntherapie/", "https://www.iozk.de/portfolio-item/video-immunologische-krebstherapie-am-iozk-in-koeln/", "https://www.iozk.de/portfolio-item/informationsbroschuere-der-iozk-stiftung/", "https://www.iozk.de/portfolio-item/personalisierte-medizin-am-iozk/", "https://www.iozk.de/portfolio-item/die-entstehung-von-krebs/", "https://www.iozk.de/portfolio-item/was-bedeutet-immuntherapie/", "https://www.iozk.de/portfolio-item/nobelpreise-fuer-immuntherapie/", "https://www.iozk.de/portfolio-item/curcumin-in-der-medizinischen-anwendung/", "https://www.iozk.de/portfolio-item/virotherapie-mit-viren-gegen-den-krebs/", "https://www.iozk.de/portfolio-item/dendritische-zellen-informieren-das-immunsystem/", "https://www.iozk.de/portfolio-item/hyperthermie-mit-waerme-gegen-krebs/", "https://www.iozk.de/tag/brustkrebs/", "https://www.iozk.de/tag/case-report/", "https://www.iozk.de/tag/check-point-inibitoren/", "https://www.iozk.de/tag/chemotherapie/", "https://www.iozk.de/tag/curamun/", "https://www.iozk.de/tag/curcumin/", "https://www.iozk.de/tag/dendritische-zellen/", "https://www.iozk.de/tag/dr-dirk-lorenzen/", "https://www.iozk.de/tag/dr-wilfried-stuecker/", "https://www.iozk.de/tag/evidenzbasierte-medizin/", "https://www.iozk.de/tag/fluessigbiopsie/", "https://www.iozk.de/tag/german-medical-award/", "https://www.iozk.de/tag/glioblastom/", "https://www.iozk.de/tag/hirntumor/", "https://www.iozk.de/tag/hyperthermie/", "https://www.iozk.de/tag/immuntherapie/", "https://www.iozk.de/tag/io-vac/", "https://www.iozk.de/tag/iozk-symposium/", "https://www.iozk.de/tag/iozk-arbeitsgruppe/", "https://www.iozk.de/tag/iozk-immuntherapie/", "https://www.iozk.de/tag/iozk-patientenbroschuere/", "https://www.iozk.de/tag/iozk-stiftung/", "https://www.iozk.de/tag/newcastle-disease-virus/", "https://www.iozk.de/tag/nobelpreis-fuer-medizin/", "https://www.iozk.de/tag/onkologie/", "https://www.iozk.de/tag/onkolytische-viren/", "https://www.iozk.de/tag/paul-ehrlich-preis/", "https://www.iozk.de/tag/personalisierte-medizin/", "https://www.iozk.de/tag/ponsgliom/", "https://www.iozk.de/tag/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/tag/prostatakrebs/", "https://www.iozk.de/tag/publikationen-dr-wilfried-stuecker/", "https://www.iozk.de/tag/publikationen-prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/tag/publikationen-stefaan-van-gool-md-phd/", "https://www.iozk.de/tag/stefaan-van-gool/", "https://www.iozk.de/tag/target-therapie/", "https://www.iozk.de/tag/virotherapie/", "tel:004922142039925", "mailto:info@iozk.de", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/impressum/", "https://www.iozk.de/datenschutzerklaerung/", "https://www.iozk.de/datenschutz/#BorCook", "https://www.iozk.de/presse/", "#top"]}